Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

BACKGROUND: Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FGF recept...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Cancer Med
Hoofdauteurs: Lee, Eudocia Q., Muzikansky, Alona, Duda, Dan G., Gaffey, Sarah, Dietrich, Jorg, Nayak, Lakshmi, Chukwueke, Ugonma N., Beroukhim, Rameen, Doherty, Lisa, Laub, Caroline Kane, LaFrankie, Debra, Fontana, Brittney, Stefanik, Jennifer, Ruland, Sandra, Caruso, Victoria, Bruno, Jennifer, Ligon, Keith, Reardon, David A., Wen, Patrick Y.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2019
Onderwerpen:
Clinical Cancer Research
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://ncbi.nlm.nih.gov/pubmed/31444999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2505
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items